Halozyme Therapeutics | HALO - Umsatzkosten





Umsatzkosten Veränderung Datum
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 211.12M 56.6M 2026-03
Amarin USD 26.05M 1.41M 2025-12
Amgen USD 1.6B 187M 2026-03
Baxter International USD 1.81B 587M 2026-03
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 160K 104.24M 2026-03
Eli Lilly USD 3.58B 205M 2026-03
Esperion Therapeutics USD 27.85M 13.43M 2025-12
Halozyme Therapeutics USD 108.75M 6.6M 2026-03
Intrexon USD 1.01M 344K 2024-06
Ionis Pharmaceuticals USD 3M 5M 2026-03
MannKind USD 39.58M 5.94M 2026-03
Minerva Neurosciences 386K 31K 2024-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Pfizer USD 4.59B 1.7B 2026-03
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
United Therapeutics USD 133.4M 341.3M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12